• U.S. Burden of Skin and Subcutaneous Diseases Increasing

    Healthday News Conditions, HealthDay News Physician's Briefing June 25, 2020
  • Can dermatology employers require employees to receive the COVID-19 vaccine?

    American Academy of Dermatology AAD, Conditions, Coronavirus, COVID-19 January 28, 2021
  • THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS

    American Academy of Dermatology AAD, Atopic Dermatitis, Conditions, Dermatology January 26, 2021
  • Expression of retinoid receptors in hand eczema.

    ClinOwl Atopic Dermatitis, ClinOwl, Conditions, Eczema October 1, 2020
  • S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants

    Healthday News Atopic Dermatitis, Conditions, Eczema July 28, 2020
  • Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.

    ClinOwl ClinOwl, Conditions, COVID-19, Psoriasis July 26, 2020

DermConnect® is an official licensee of the American Academy of Dermatology.

DermConnect®
Navigation
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma
Home 2020 October 2

Post Archive by Day

Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis a multicenter, double-blind, randomized controlled study.

In Dermatology
by ClinOwl
October 2, 2020

Capsule summary Despite the absence of robust evidence, tacrolimus is quite commonly used off label as maintenance treatment for seborrheic dermatitis, in clinical practice. Tacrolimus 0.1% ointment applied twice a …

Topical anti-microbial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild-to-moderate atopic dermatitis in a phase 2 randomized controlled trial.

In Dermatology
by ClinOwl
October 2, 2020

Dysbiosis and colonization with Staphylococcus aureus is considered to play an important role in the pathogenesis of atopic dermatitis (AD). Recovering this dysbiosis may improve AD symptoms. Omiganan is a …

Cutaneous toxicities in melanoma patients receiving checkpoint inhibitor therapy, a retrospective review: The experience of a single large specialist institution.

In Dermatology
by ClinOwl
October 2, 2020

CPI was approved by the European Medicines Agency (EMA) in 2012 for advanced melanoma and extended to include adjuvant melanoma treatment in 2018. Expectation for survival in advanced melanoma now …

Comparison of efficacy of noncultured hair follicle cell suspension and noncultured epidermal cell suspension in repigmentation of leukotrichia and skin patch in vitiligo: a randomized trial.

In Dermatology
by ClinOwl
October 2, 2020

Vitiligo manifests as hypo- to de-pigmented macules, which are sometimes associated with leukotrichia. For complete cosmetic improvement, the repigmentation of leukotrichia is an important component.This randomized controlled trial included patients …

Dupilumab treatment ameliorates clinical and hematological symptoms, including blood eosinophilia, in patients with atopic dermatitis.

In Dermatology
by ClinOwl
October 2, 2020

Atopic dermatitis (AD) is an allergic disease that affects individuals of various ages. Recently, the IL-4/13 inhibitor dupilumab has gained regulatory approval for clinical use in AD patients. Dupilumab has …

View Post

Immunotherapy Combo Treats Advanced Kidney Cancer

In HealthDay News
by Healthday
October 2, 2020

First results show survival benefit with nivolumab plus cabozantinib versus sunitinib

View Post

Ductal Carcinoma In Situ Tied to Threefold Higher Risk for Death

In HealthDay News
by Healthday
October 2, 2020

Risk for dying from breast cancer remains elevated 15 years after initial diagnosis

View Post

Mortality Below 40 Percent for COVID-19 Patients Put on ECMO

In HealthDay News
by Healthday
October 2, 2020

Cumulative incidence of in-hospital mortality estimated to be 37.4 percent at 90 days

View Post

Considerable State-Level Variation Found in Prevalence of Eclampsia

In HealthDay News
by Healthday
October 2, 2020

Variation between states modest in chronic hypertension, hypertensive disorders of pregnancy

View Post

Antibodies Decrease With Time After COVID-19 Symptom Onset

In HealthDay News
by Healthday
October 2, 2020

For all donors of convalescent plasma, drop seen in anti-RBD antibody levels from first to last donation

  • Page 1 of 3
  • 1
  • 2
  • 3
  • →

TRENDING

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease
  • Lymph Node Dissection Declining in SLN-Positive Melanoma
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

LATEST ARTICLES

  • Dose Range for Iberdomide Studied in Systemic Lupus Erythematosus March 16, 2022
  • YouTube Video Quality for Aesthetic Injectables Lower Than Quality of Websites March 11, 2022
  • Cardiac Biomarkers and CV Risk Examined in Psoriatic Disease March 11, 2022
  • Lymph Node Dissection Declining in SLN-Positive Melanoma March 9, 2022
  • Debt Valuation of Private Equity-Backed Dermatology Groups Down March 9, 2022

Quick Links

  • Home
  • Atopic Dermatitis
  • Psoriasis
    • Chronic Plaque Psoriasis
    • Guttate Psoriasis
  • Skin Cancer
    • Basal Cell Carcinoma
    • Cutaneous T-cell Lymphoma
    • Dermatofibrosarcoma Protuberans (DFSP)
    • Melanoma
    • Merkel Cell Carcinoma
    • Sebaceous Carcinoma
    • Squamous Cell Carcinoma

About DermConnect®

DermConnect® curates the latest in dermatology news and resources from some of the most trusted and respected names in healthcare, including the American Academy of Dermatology, ClinOwl, HealthDay and Dermnet NZ.

SCHEDULE

October 2020
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
« Sep   Nov »

All content indicated on this website as authored by "AAD" is owned by and licensed with the permission of the American Academy of Dermatology (“AAD”) for personal educational use.

The content may not be distributed in whole or in part to any third parties without express written permission from AAD,
nor may viewers of this site translate, edit, modify or otherwise create derivative works from the content.

The licensing of the content by AAD does not constitute or imply any endorsement of any company and/or any of its goods, services or written work product.

 

  • Home
  • Atopic Dermatitis
  • Psoriasis
  • Skin Cancer